Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab withdrawal-retreatment study in non-radiographic axial spondyloarthritis remission
NL-OMON55967Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in non-radiographic axial spondyloarthritis (nr-axSpA) comparing Continuous secukinumab after remission with Placebo withdrawal after remission (2 arms). Primary endpoint: Proportion of participants remaining flare-free at Week 120. Started Nov 2023; status: recruiting.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON55967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55967.